Elabscience
SKU:E-AB-F1126M
AF647 Anti-Human CD1a Antibody[OKT-6]
AF647 Anti-Human CD1a Antibody[OKT-6]
Couldn't load pickup availability
AF647 Anti-Human CD1a Antibody[OKT-6]
The AF647 Anti-Human CD1a Antibody[OKT-6] is a highly specific and reliable tool for immunohistochemistry (IHC) and flow cytometry applications. This monoclonal antibody is designed to target the CD1a protein, which is expressed on the surface of human dendritic cells and Langerhans cells. With its exceptional sensitivity and specificity, this antibody enables researchers to accurately identify and analyze CD1a-positive cells in various tissues and biological samples.
This AF647 Anti-Human CD1a Antibody[OKT-6] offers exceptional performance in IHC staining, allowing for precise visualization of CD1a expression patterns in tissue sections. It exhibits minimal background staining, ensuring reliable and accurate results. The antibody is optimized for use in formalin-fixed, paraffin-embedded (FFPE) tissues, making it suitable for a wide range of clinical and research applications.
In addition to its application in IHC, this antibody is also highly suitable for flow cytometry analysis. It enables researchers to identify and quantify CD1a-positive cells in suspension, providing valuable insights into the distribution and abundance of these cells in various biological samples. The AF647 Anti-Human CD1a Antibody[OKT-6] is validated for use in human samples, ensuring its reliability and accuracy in diverse research settings.
Overall, the AF647 Anti-Human CD1a Antibody[OKT-6] is a powerful tool for researchers studying dendritic cells, Langerhans cells, and related immune responses. Its exceptional sensitivity, specificity, and versatility make it an invaluable asset in immunohistochemistry and flow cytometry experiments. With this antibody, researchers can confidently explore the role of CD1a-positive cells in various physiological and pathological processes, advancing our understanding of the immune system and potentially leading to the development of novel therapeutic strategies.
Share
